# Pharmacodynamics Study of MRX34, MicroRNA Liposomal Injection in Melanoma Patients With Biopsy Accessible Lesions

> **NCT02862145** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Mirna Therapeutics, Inc.**

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** MRX34
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02862145
- **Lead sponsor:** Mirna Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-08
- **Primary completion:** 2017-09
- **Final completion:** 2017-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** 5 immune related serious adverse events in Phase 1 study
- **Last updated:** 2016-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02862145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02862145, "Pharmacodynamics Study of MRX34, MicroRNA Liposomal Injection in Melanoma Patients With Biopsy Accessible Lesions". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02862145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*